Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof: Individuel monitorering af biotilgængelighed og immunogenicitet-- sekundærpublikation

Klaus Bendtzen; Pierre Geborek; Morten Svenson; Lotta Larsson; Meliha C Kapetanovic; Tore Saxne

Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof: Individuel monitorering af biotilgængelighed og immunogenicitet-- sekundærpublikation

Translated title of the contribution: [Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity--secondary publication]

Klaus Bendtzen, Pierre Geborek, Morten Svenson, Lotta Larsson, Meliha C Kapetanovic, Tore Saxne

Abstract

Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.

Translated title of the contribution	[Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity--secondary publication]
Original language	Danish
Journal	Ugeskrift for Laeger
Volume	169
Issue number	5
Pages (from-to)	420-3
Number of pages	4
Publication status	Published - 29 Jan 2007

Fingerprint

Dive into the research topics of '[Treatment of rheumatoid arthritis (RA) with anti-TNF-alpha antibody (Remicade). Individual monitoring of bioavailability and immunogenicity--secondary publication]: Individuel monitorering af biotilgængelighed og immunogenicitet-- sekundærpublikation'. Together they form a unique fingerprint.

Cite this

Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof: Individuel monitorering af biotilgængelighed og immunogenicitet-- sekundærpublikation. / Bendtzen, Klaus; Geborek, Pierre; Svenson, Morten et al.
In: Ugeskrift for Laeger, Vol. 169, No. 5, 29.01.2007, p. 420-3.

Research output: Contribution to journal › Journal article › Research › peer-review

@article{1305bb5bc9324172bc558c80d876b14d,

title = "Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof: Individuel monitorering af biotilg{\ae}ngelighed og immunogenicitet-- sekund{\ae}rpublikation",

abstract = "Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.",

author = "Klaus Bendtzen and Pierre Geborek and Morten Svenson and Lotta Larsson and Kapetanovic, {Meliha C} and Tore Saxne",

year = "2007",

month = jan,

day = "29",

language = "Dansk",

volume = "169",

pages = "420--3",

journal = "Ugeskrift for Laeger",

issn = "1399-4174",

publisher = "Almindelige Danske Laegeforening",

number = "5",

}

TY - JOUR

T1 - Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof

T2 - Individuel monitorering af biotilgængelighed og immunogenicitet-- sekundærpublikation

AU - Bendtzen, Klaus

AU - Geborek, Pierre

AU - Svenson, Morten

AU - Larsson, Lotta

AU - Kapetanovic, Meliha C

AU - Saxne, Tore

PY - 2007/1/29

Y1 - 2007/1/29

N2 - Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.

AB - Remicade/infliximab is effective in rheumatoid arthritis (RA), but response failure is frequent. Sera from 106 RA patients were monitored using an RIA for functional infliximab and an RIA for anti-infliximab antibody (Ab). S-infliximab varied considerably, e.g. 0-22 microg/ml before the 3rd infusion, and 44% were Ab-positive after 6 months. Low s-infliximab was associated with Ab development and later therapeutic failure, and high Ab levels could be related to dose increases, side-effects and cessation of therapy. Pharmacological monitoring should help optimize anti-TNF therapies.

UR - https://ugeskriftet.dk/videnskab/behandling-af-reumatoid-artrit-med-anti-tumornekrosefaktor-antistof-individuel

M3 - Tidsskriftartikel

C2 - 17280636

SN - 1399-4174

VL - 169

SP - 420

EP - 423

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 5

ER -

Behandling af reumatoid artrit med anti-tumornekrosefaktor-alpha-antistof: Individuel monitorering af biotilgængelighed og immunogenicitet-- sekundærpublikation

Abstract

Other files and links

Fingerprint

Cite this